Evidence map›Paper›PMID 26279835›Full record

ArticleInfectious diseases of poverty2015

Hypo-endemic onchocerciasis hotspots: defining areas of high risk through micro-mapping and environmental delineation.

Louise A Kelly-Hope, Thomas R Unnasch, Michelle C Stanton, David H Molyneux

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  7. Projected Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  8. Article
  9. Review
  10. Article
  11. In Southern NigeriaThe American journal of tropical medicine and hygiene · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Neglected Tropical Diseases: Epidemiology and Global Burden.Tropical medicine and infectious disease · 2017
    Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Louise A Kelly-HopeLiverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA UK.
Thomas R UnnaschUniversity of South Florida, Tampa, Florida USA.
Michelle C StantonLiverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA UK.
David H MolyneuxLiverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA UK.
Liverpool School of Tropical Medicine · GBUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOnchocerciasis (river blindness) caused by the parasite Onchocercavolvulus and transmitted by riverine Simulium spp. (Black flies) is targeted for elimination in Africa. This is a significant change in strategy from the 'control' of meso- and hyper-endemic areas through mass drug administration (MDA) with Mectizan® (ivermectin), to the 'elimination' in all endemic areas where a range of interventions may be required. The most significant challenges of elimination in low transmission or hypo-endemic areas are two-fold. First, there are vast remote areas where the focality of low transmission is relatively undefined. Second, the treatment with ivermectin increases the risk of serious adverse events (SAEs) in individuals with high parasitaemias of Loa loa, a filarial parasite widespread in Central and West Africa, which causes Tropical eye worm and transmitted by Chrysops spp. (Deer flies). DISCUSSION: We therefore propose novel mapping approaches using remote sensing satellite and modelled environmental data to be used in combination with rapid field surveys to help resolve the problems of targeting the expansion of onchocerciasis elimination activities in L. loa co-endemic areas. First, we demonstrate that micro-stratification overlap mapping (MOM) of available onchocerciasis and loiasis prevalence maps can be used to identify 12 key high risk areas, where low O. volvulusand high L. loa transmission overlap, which we define as "hypo-endemic hotspots". Second we show that integrated micro-mapping of prevalence data, and the use of environmental data to delineate riverine and forest risk factors associated with Simulium spp. and Chrysops spp. vector habitats can further help to define target intervention areas i.e. secondary hotspots within hotspots, to help avoid the risk of SAEs. SUMMARY: These mapping examples demonstrate the value of bringing prevalence, entomological and ecological information together to develop maps for planned implementation and targeted strategies. This is critical as better mapping may the reduce costs and lower the L. loa associated risks, especially if there are extensive areas of low endemicity that may require treatment with ivermectin or alternative strategies. Novel cost-effective approaches are necessary if elimination of O.volvulus transmission in Africa is to be achieved in an efficient and safe way by the goal of 2025.

Indexed as

AdultAfrica, CentralAfrica, WesternEnvironmentFemaleHumansMaleMiddle AgedOnchocerciasisPrevalenceRemote Sensing TechnologyRiskAfricaEliminationEnvironmentLoa loaLoiasisMappingOnchocerciasisRiver blindnessSevere adverse events

Identifiers

PMID26279835
PMCPMC4537576
OpenAlexW1550107760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.